As a legacy 'sick care' company, its business model is considered at risk due to the rise of preventative healthcare platforms like HIMS, which aim to intervene before patients develop chronic conditions requiring dialysis.

Mentioned as a large dialysis organization that is expected to ramp up adoption of CoreMedix's DefenCath product, which would drive significant revenue for CRMD.